Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-06-02
1998-02-24
Higel, Floyd D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514397, 514398, 514400, 514401, 5483111, 5483275, 5483425, C07D23302, C07D23304, C07D23354, C07D23328, C07D23368, A61K 31415
Patent
active
057212651
ABSTRACT:
Agents useful for detecting hypoxic tumor cells are provided. The compounds have the structural formula (I) ##STR1## Methods of using the compounds to detect hypoxic tumor cells are also provided, as are pharmaceutical compositions formulated with the novel compounds.
REFERENCES:
patent: 3679698 (1972-07-01), Beaman et al.
patent: 4977273 (1990-12-01), Kagiya et al.
patent: 5304654 (1994-04-01), Kagiya et al.
Brown et al., "Partition Coefficient as a Guide to the Development of Radiosensitizers Which are Less Toxic than Misonidazole," Radiation Res. 82:171-190 (1980).
Brown et al., "SR-2508: A 2-Nitroimidazole Amide which Should Be Superior to Misonidazole as a Radiosensitizer for Clinical Use," Int. J. Rad. Oncol. Biol. Phys. 7:695-703 (1981).
Dabrow et al., "Molecular Dimensions and Properties of Biophys. 302:259-264 (1993).
Evelhoch et al., "A Method for Direct in Vivo Measurement of Drug Concentrations from a Single .sup.2 H NMR Spectrum," Magn. Reson. Med. 9:402-410 (1989).
Jin et al., "Dynamic measurements of hexafluoromisonidazole (CCI-103F) retention in mouse tumours by .sup.1 H/.sup.19 F magnetic resonance spectroscopy," Int. J. Radiation Biol. 58:1025-1034(1990).
Kwock et al., "Evaluation of a Fluorinated 2-Nitroimadazole Binding to Hypoxic Cells in Tumor-Bearing Rats by .sup.19 F Magnetic Resonance Spectroscopy and Immunohistochemistry," Radiation Res. 129:71-78 (1992).
Li et al., "Prediction of Tumor Radiosensitivity by Hexafluoromisonidazole Spectroscopy," Cancer Comm. 3:133-139 (1991).
Mannan et al., "Radioiodinated 1-(2-Fluoro-4-iodo-2,4-dideoxy-.beta.-L-xylopyranosyl)-2-nitroimidazole: A Novel Probe for the Noninvasive Assessment of Tumor Hypoxia," Radiation Res. 132:368-374 (1992).
Mashiba et al., "Enhancement of Radiosensitizing Effect of the Nitroimadazole Derivative RK28 on the Proliferation of MethA Tumor Cells in Combined Use with Diethyldithio-carbamate," Life Sciences 49:1419-142A5 (1991).
Maxwell et al., "Demonstration of Tumor-Selective Retention of Fluorinated Nitroimadazole Probes by .sup.19 F Magnetic Resonance Spectroscopy in Vivo," Int. J. Radiation Oncol. Biol. Phys. 16:925-929 (1989).
Murayama et al., "Radiosensitization by a New Nucleoside Analogue: Int. J. Radiation Oncol. Biol. Phys. 17:575-581 (1989).
Raleigh et al., "Development of an in Vivo .sup.19 F Magnetic Resonance Method for Measuring Oxygen Deficiency in Tumors," Magn. Reson. Med. 22:451-466 (1991).
Raleigh et al., "Covalent binding of a Fluorinated 2-Nitroimidazole to EMT-6 Tumors in Balb/C Mice: Detection by F-19 Nuclear magnetic Resonance at 2.35 T," Int. J. Radiation Oncol. Biol. Phys. 12:1243-1245 (1986).
Sasai et al., "A Fluorinated 2-Nitroimidazole, KU-2285, as a New Hypoxic Cell Radiosensitizer," Int. J. Radiation Oncol. Biol. Phys. 20:1249-1254 (1991).
Sasai et al., "In Vivo Radiosensitizing Activity of a New Fluorinated Hypoxic Cell Radiosensitizer, KU-2285, in Combination with Radiation Dose Fractionation," Int. J. Radiation Oncol. Biol. Phys. 21:1231-1234 (1991) (last page missing).
Shibamoto et al., "Radiosensitization efficacy of KU-2285, RP-170 and etanidazole at low radiation doses: assessment by in vitro cytokinesis-block micronucleus assay," Int. J. Radiation Biol. 61:473-478 (1992).
Shibamoto et al., "Evaluation of a new 2-nitroimidazole nucleoside analogue, RK-28 as a radiosensitizer for clinical use," Int. J. Radiation Biol. 59:105-115 (1991).
Shibamoto et al., "Characterisitcs of Fluorinated Nitroazoles as Hypoxic Cell Radiosensitizers," Int. J. Radiation Oncol. Biol. Phys. 16:1045-1048 (1989).
Workman et al., "Non-invasive MRS in New Anticancer Drug Development," NMR Biomed. 5:270-272 (1992).
Workman et al., "Structure-pharmacokinetic Relationships for Misonidazole Analogues in Mice," Cancer Chemother. Pharmacol. 6:39-49 (1981).
Jin et al., "Dynamic measurements of hexafluoromisonidazole (CCI-103F) retention in mouse tumours by .sup.1 H/.sup.19 F magnetic resonance spectroscopy" (1990) Int. J. Radiation Biol. 58:1025-1034.
Kwock et al., "Evaluation of a Fluorinated 2-Nitroimadazole Binding to Hypoxic Cells in Tumor-Bearing Rats by .sup.19 F Magnetic Resonance Spectroscopy and Immunohistochemistry" (1992) Radiation Res. 129:71-78.
Li et al., "Prediction of Tumor Radiosensitivity by Hexafluoromisonidazole Spectroscopy" (1991) Cancer Comm. 3:133-139.
Mannan et al., "Radioiodinated 1-(2-Fluoro-4-iodo-2,4-dideoxy-/.beta.-L-xylopyranosyl)-2-nitroimidazole: A Novel Probe for the Noninvasive Assessment of Tumor Hypoxia" (1992) Radiation Res. 132:368-374.
Mashiba et al., "Enhancement of Radiosensitizing Effect of the Nitroimadazole Derivative RK28 on the Proliferation of MethA Tumor Cells in Combined Use with Diethyldithio-carbamate" (1991) Life Sciences 49:1419-1425.
Maxwell et al, "Demonstration of Tumor-Selective Retention of Fluorinated Nitroimadazole Probes by .sup.19 F Magnetic Resonance Spectroscopy in Vivo" (1989) Int. J. Radiation Oncol. Biol. Phys. 16:925-929.
Murayama et al., "Radiosensitization by a New Nucleoside Analogue: (1989) Int. J. Radiation Oncol. Biol. Phys. 17:575-581.
Raleigh et al. "Development of an in Vivo .sup.19 F Magnetic Resonance Method for Measuring Oxygen Deficiency in Tumors" (1991) Magn. Reson. Med. 22:451-466.
Raleigh et al., "Covalent binding of a Fluorinated 2-Nitroimidazole to EMT-6 Tumors in Balb/C Mice: Detection by F-19 Nuclear magnetic Resonance at 2.35 T" (1986) Int. J. Radiation Oncol. Biol. Phys. 12:1243-1245.
Sasai et al., "A Fluorinated 2-Nitroimidazole, KU-2285, as a New Hypoxic Cell Radiosensitizer" (1991) Int. J. Radiation Oncol. Biol. Phys. 20:1249-1254.
Sasai et al., "In Vivo Radiosensitizing Activity of a New Fluorinated Hypoxic Cell Radiosensitizer, KU-2285, in Combination with Radiation Dose Fractionation" (1991) Int. J. Radiation Oncol. Biol. Phys. 21:1231-1234.
Shibamoto et al., "Radiosensitization efficacy of KU-2285, RP-170 and etanidazole at low radiation doses: assessment by in vitro cytokinesis-block micronucleus assay" (1992) Int. J. Radiation Biol. 61:473-478.
Shibamoto et al., "Evaluation of a new 2-nitroimidazole nucleoside analogue, RK-28 as a radiosensitizer for clinical use" (1991) Int. J. Radiation Biol. 59:105-115.
Shibamoto et al., "Characterisitcs of Fluorinated Nitroazoles as Hypoxic Cell Radiosensitizers" (1989) Int. J. Radiation Oncol. Biol. Phys. 16:1045-1048.
Workman et al., "Non-invasive MRS in New Anticancer Drug Development" (1992) NMR Biomed. 5:270-272.
Workman et al., "Structure-pharmacokinetic Relationships for Misonidazole Analogues in Mice" (1981) Cancer Chemother. Pharmacol. 6:39-49.
Maxwell et al., "Demonstration of Tumor-Selective Retention of Fluorinated Nitroimidazole Probes by Florine-19 Magnetic Resonance Spectroscopy In Vivo," Chemical Abstracts 111(7):53409g (1989) (see also, Int. J. radiat. Oncol., Biol. Phys. 16(4):925-9 (1989).
Aboagye Eric O.
Kelson Andrew B.
Lewis Alexander D.
Tracy Michael
Workman Paul
Higel Floyd D.
Reed Dianne E.
SRI - International
LandOfFree
Fluorinated 2-nitroimidazole analogs for detecting hypoxic tumor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fluorinated 2-nitroimidazole analogs for detecting hypoxic tumor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fluorinated 2-nitroimidazole analogs for detecting hypoxic tumor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1875571